- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.07. | OnKure Therapeutics, Inc.: OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Ka Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026 | 2 | GlobeNewswire (USA) | ||
| 05.06. | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 04.06. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.05. | OnKure Therapeutics GAAP EPS of -$1.11 misses by $0.37 | 4 | Seeking Alpha | ||
| ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 30.03. | Leerink cuts OnKure stock price target on strategic shift | 2 | Investing.com | ||
| 30.03. | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.03. | Oppenheimer reiterates OnKure stock rating on pipeline shift | 1 | Investing.com | ||
| 27.03. | OnKure Therapeutics prices $150M oversubscribed private placement | 1 | Seeking Alpha | ||
| 27.03. | OnKure raises $150M to advance breast cancer programs | 1 | Investing.com | ||
| 12.03. | OnKure Therapeutics GAAP EPS of -$0.09 | 2 | Seeking Alpha | ||
| 12.03. | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 12.03. | OnKure Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 12.03. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.11.25 | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update | 296 | GlobeNewswire (Europe) | -- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,910 | -0,27 % | RBC stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Pfizer mit einem Kursziel von 25 US-Dollar auf "Sector Perform" belassen. Seine Umsatzschätzung entspreche dem Konsens, schrieb... ► Artikel lesen | |
| INNOCAN PHARMA | 1,925 | +6,35 % | INNOCAN PHARMA CORPORATION zeigt nachhaltige Stärke | ||
| QUANTUM BIOPHARMA | 2,796 | -0,71 % | Quantum BioPharma Provides Corporate Update | THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, July 07, 2026... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 24,550 | +8,87 % | Assembly Biosciences: Der wichtigste HSV-Moment der Biotech-Geschichte steht bevor | Während sich die Biotech-Welt seit Jahren auf Themen wie Adipositas, neuartige Krebstherapien und künstliche Intelligenz fokussiert, könnte sich im Hintergrund eine der größten unentdeckten Chancen... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 59,22 | +0,99 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 3,465 | -1,98 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| OPKO HEALTH | 1,050 | +0,96 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results | MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first... ► Artikel lesen | |
| JAGUAR HEALTH | 1,370 | +2,62 % | Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Under Review | Original-Research: Jaguar Health Inc - from First Berlin Equity Research GmbH
17.07.2026 / 17:49 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| OPUS GENETICS | 2,900 | +1,40 % | Opus Genetics, Inc.: Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results | RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the "Company", "Opus Genetics" or "Opus"), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| SOLIGENIX | 0,355 | -1,42 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results | PRINCETON, N.J., May 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| KALA BIO | 0,820 | -3,19 % | XFRA 27F: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKALA BIO INC. O.N.... ► Artikel lesen | |
| PROTHENA | 7,392 | -0,22 % | Prothena Corporation plc: Prothena Reports First Quarter 2026 Financial Results and Business Highlights | Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million
Prothena updates... ► Artikel lesen | |
| EVOLUS | 4,974 | +1,06 % | Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo in the United States, Expanding Its Injectable Portfolio into Skin Quality | Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an exclusive licensing and... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 3,805 | +2,56 % | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute | WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx" or the "Company") today issued the following statement in response to recent public claims made... ► Artikel lesen | |
| NEUROGENE | 30,600 | -4,38 % | Morning Market Movers: Neurogene, Duolingo, Xponential Fitness, Emergent BioSolutions See Big Swings | WASHINGTON (dpa-AFX) - At 6:22 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
Das Unternehmen ONKURE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,68 % bei einem Aktienkurs von 4,210 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONKURE THERAPEUTICS INC finden Sie auf Wallstreet Online.